Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $40 from $30 and keeps a Buy rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
- Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)
- Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing
- Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating
- Viridian Therapeutics submits BLA to the FDA for veligrotug